Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Annexin A1 as a Potential Prognostic Biomarker for COVID-19 Disease: Case-Control Study

NCT04948229 is registered in ClinicalTrials.gov with Kafkas University as lead sponsor.

NCT NCT04948229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04948229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Annexin A1 as a Potential Prognostic Biomarker for COVID-19 Disease: Case-Control Study
Lead sponsor
Kafkas University
Phase
Observational
Overall status
Completed
Start date
February 10, 2021
Completion date
March 16, 2021
Enrollment
124 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenal cortex hormones, annexin a1